BMS-790052
Sponsors
Bristol-Myers Squibb
Conditions
Chronic Hepatitis CHepatic InsufficiencyHepatitis CHepatitis C InfectionHepatitis C Virus
Phase 1
Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment
CompletedNCT00859053
Start: 2009-03-31End: 2009-09-30Updated: 2015-10-08
Drug-Drug Interaction Study in Healthy Subjects
CompletedNCT00904059
Start: 2009-05-31End: 2009-07-31Updated: 2011-01-07
Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects
CompletedNCT00983957
Start: 2009-10-31End: 2010-02-28Updated: 2015-10-16
Phase 2
Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care
CompletedNCT01012895
Start: 2009-12-31End: 2014-02-28Updated: 2015-10-09
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients
CompletedNCT01016912
Start: 2009-12-31End: 2010-09-30Updated: 2015-10-12
An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject
CompletedNCT01051414
Start: 2010-04-30End: 2012-05-31Updated: 2015-10-09
Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment
CompletedNCT01170962
Start: 2010-08-31End: 2012-12-31Updated: 2015-10-12
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
CompletedNCT01455090
Start: 2011-11-30End: 2015-07-31Updated: 2017-04-27